查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969416

纖維瘤市場：按治療方法、藥物、腫瘤部位、最終用戶和年齡層別分類 - 2026-2032 年全球預測

Desmoid Tumors Market by Treatment Type, Drug Type, Tumor Location, End User, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，纖維瘤市值將達到 28.3 億美元，到 2026 年將達到 30 億美元。以 6.14% 的複合年成長率計算，預計到 2032 年將達到 43 億美元。

主要市場統計數據
基準年 2025 28.3億美元
預計年份：2026年 30億美元
預測年份 2032 43億美元
複合年成長率 (%) 6.14%

全面闡述研究、治療和策略性決策纖維瘤所需的生物學特徵、臨床複雜性和跨學科重點。

侵襲性纖維瘤（也稱為侵襲性纖維瘤病）在臨床和診療方面具有獨特的挑戰，需要多學科協作。這些局部侵襲性軟組織腫瘤起源於間質結締組織，其臨床表現難以預測，從緩慢穩定到持續局部侵襲，均可危害器官功能和生活品質。值得注意的是，通常不會發生轉移，因此治療目標也從根治性全身清除轉變為持續控制和功能保留。

分子層次理解、以病人為中心的管理方法和轉化策略的變革性進步，重新定義了治療發展和護理路徑。

近年來，纖維瘤的診斷、臨床管理和治療研發正經歷著變革性的轉變。分子病理學的進步加深了我們對纖維瘤潛在生物學機制的理解，特別是WNT訊號通路的異常調控以及BETA-catenin訊號通路的作用，從而能夠更合理地選擇靶點並採用基於生物標記的治療方法。因此，製藥公司正擴大研發阻斷特定訊號傳遞的介入措施，而臨床醫師也正將分子譜分析整合到診斷流程中，以最佳化治療方案。

評估 2025 年美國關稅變化和貿易政策趨勢對供應鏈、臨床試驗物流、籌資策略和跨境合作的影響。

政策和貿易趨勢對治療方法的可近性和全球臨床開發網路的運作起著至關重要的作用。美國將於2025年實施的關稅措施將為參與纖維瘤研究和治療的相關人員帶來新的營運複雜性。關稅調整將影響活性藥物成分、醫療設備、影像設備和介入手術用一次性耗材的進口成本和及時性，進而影響醫院和專科診所的採購決策。此外，上游供應鏈的中斷可能會促使申辦者重新評估其製造地和臨床試驗材料分發的緊急時應對計畫，尤其是在依賴跨境物流的多國研究中。

詳細的細分分析顯示治療方法、藥物分類、腫瘤解剖部位、醫療保健服務環境和患者年齡層如何共同影響臨床決策和就醫途徑。

細緻的細分觀點凸顯了臨床實務、治療途徑和研發重點的異質性。在按治療類型進行分析時，相關人員需要認知到治療頻譜的廣泛性，其中包括：使用他莫昔芬和托瑞米芬等藥物的抗激素荷爾蒙療法；基於多柔比星的治療方案；細胞毒性療法，例如胺基甲基葉酸聯合長春鹼和聚乙二醇化脂質體局部柔比星；繼續發揮非類固醇消炎劑治療的放射線治療的非針對藥物治療治療的針對標靶治療頻譜。每種治療方法都存在獨特的療效和耐受性權衡，這些權衡會影響治療順序的確定。

一項對美洲、歐洲、中東和非洲以及亞太地區進行的區域分析突顯了在獲取途徑、監管和基礎設施方面存在的差異，這些差異影響著臨床研究和患者照護。

區域趨勢對診斷方法、治療方法的可近性、監管以及臨床創新步伐都具有深遠的影響。在美洲，完善的臨床研究基礎設施、成熟的轉診網路以及活躍的患者權益倡導團體，為有前景的治療方法快速進入後期臨床試驗階段提供了支持。然而，不同次區域間支付方政策和醫療資源取得的差異，可能會影響治療方法在實際臨床實踐中的推廣和應用。區域數據系統和註冊登記系統通常有助於長期追蹤患者情況，從而提高真實世界證據的質量，並促進核准後監測工作。

從公司觀點揭示夥伴關係策略、轉化方法和商業化重點，以加速治療方案的發展和纖維瘤病證據的產生。

參與纖維瘤研究的公司的競爭與合作行為揭示了影響研發軌跡和患者用藥的重要模式。專注於分子標靶療法和新型作用機制的創新公司正與學術機構和合作研究團隊攜手，加速生物學假設的檢驗和概念驗證研究。同時，投資於製劑改進、仿單標示外用藥和適應性試驗平台的公司，可以在徵兆顯現時利用現有的安全性知識，從而更快地過渡到註冊試驗階段。

為行業領導者提供實用建議，以協調臨床開發、供應鏈韌性、報銷計劃和相關人員合作，從而滿足不斷變化的患者需求。

我們鼓勵行業領導者採取一系列合作行動，將科學進步轉化為永續的臨床和商業性影響。首先，研發策略應優先考慮以病人為中心的終點指標，並將自然病程資料和註冊登記納入試驗設計，以降低不確定性並提高相關性。適應性試驗模式和平台方法可以提高病程波動性疾病的效率和倫理平衡。同時，應謹慎使用生物標記驅動的富集策略，以維持研究結果的普適性。

我們透過高度透明的混合調查方法（包括資料來源、專家參與、分析框架和品管）為相關人員創造可操作的見解。

本執行摘要依據的研究整合了多方面的證據，從而產生了一套可靠且審核的見解。為了涵蓋已確立和新興的數據，我們從同行評審的臨床文獻、公開的臨床試驗註冊庫、監管資訊披露和會議報告記錄中收集了資訊。此外，我們還透過與關鍵意見領袖（KOL）、臨床研究人員、註冊庫管理人員和患者權益倡導組織代表進行結構化訪談，獲取了定性資訊，以補充科學記錄的真實世界觀點。

策略結論整合了科學進步、營運重點和合作機會，這些都應與改善纖維瘤患者的治療結果一致。

目前，纖維瘤的治療格局呈現出顯著的科學進展、不斷發展的臨床實踐以及不斷湧現的運作挑戰，這些因素共同構成了一個複雜而又充滿機會的領域。分子層面的發現和標靶治療方法正在提升患者獲得臨床獲益的可能性，而向保守治療和功能性終點的轉變則凸顯了以患者為中心的研發理念的重要性。同時，貿易政策的變化和供應鏈的波動等外部壓力也要求我們採取積極主動的營運策略，以確保治療的連續性和臨床試驗的完整性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法分類的纖維瘤市場

  • 抗荷爾蒙療法
    • 他莫昔芬
    • 托瑞米芬
  • 化療
    • 以多柔比星為基礎的方案
    • 胺基甲基葉酸和長春鹼
    • 聚乙二醇化脂質體阿黴素
  • 冷凍消融術
  • 非類固醇消炎劑（NSAIDs）
  • 放射線治療
  • 外科手術
  • 標靶治療

第9章 依藥物類型分類的纖維瘤市場

  • 非處方藥
  • 處方藥

第10章 按腫瘤部位分類的纖維瘤市場

  • 腹部
  • 腹部外側
  • 腹腔內

第11章 纖維瘤市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章 纖維瘤市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第13章 纖維瘤市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 纖維瘤市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 纖維瘤市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國纖維瘤市場

第17章：中國纖維瘤市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Apotex Inc.
  • Baxter International, Inc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr Reddys Laboratories Limited
  • Encapsula NanoSciences LLC
  • Fermion Oy by Orion Corporation
  • Hetero Healthcare Limited.
  • Immunome, Inc.
  • Intelicure Lifesciences
  • Iterion Therapeutics
  • Johnson & Johnson Services, Inc.
  • Mayne Pharma Group Limited
  • Medichem, SA
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • SpringWorks Therapeutics, Inc.
  • Sun Pharmaceutical Industries Limited
  • Synthon International Holding BV
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-535C629188EE

The Desmoid Tumors Market was valued at USD 2.83 billion in 2025 and is projected to grow to USD 3.00 billion in 2026, with a CAGR of 6.14%, reaching USD 4.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.83 billion
Estimated Year [2026] USD 3.00 billion
Forecast Year [2032] USD 4.30 billion
CAGR (%) 6.14%

Comprehensive framing of desmoid tumor biology, clinical complexity, and the multidisciplinary priorities necessary to guide research, care, and strategic decisions

Desmoid tumors, also known as aggressive fibromatosis, present a unique clinical and research challenge that demands a coordinated, multidisciplinary response. These locally aggressive soft tissue neoplasms arise from mesenchymal connective tissue and are characterized by unpredictable clinical behavior, ranging from indolent stability to relentless local invasion that threatens organ function and quality of life. Importantly, they do not metastasize in the classical sense, which reframes treatment objectives toward durable control and preservation of function rather than curative systemic eradication.

Clinicians face difficult trade-offs between active surveillance and interventional therapies, and the therapeutic armamentarium spans conservative pharmacologic approaches, cytotoxic regimens, targeted agents, radiation, ablation techniques, and surgery. At the same time, patient priorities emphasize symptom control, mobility, and long-term preservation of daily activities, which introduces complexity into endpoints and trial design. This landscape has spurred a shift toward patient-reported outcomes and real-world evidence as complementary data streams to traditional clinical endpoints.

Consequently, stakeholders-including clinicians, sponsors, payers, and patient advocates-must align on pragmatic frameworks for decision making that value functional outcomes and manageable toxicity profiles. Emerging molecular insights and innovative trial designs create opportunity, but translating scientific advances into better care requires rigorous evidence integration, stakeholder engagement, and operational agility. The following sections examine transformative shifts, supply chain and policy impacts, segmentation subtleties, regional contrasts, company strategies, and practical recommendations to help leaders navigate this evolving field.

Transformative shifts in molecular understanding, patient-centered management approaches, and translational strategies that are redefining therapeutic development and care pathways

The last several years have witnessed transformative shifts that are reshaping diagnosis, clinical management, and therapeutic development for desmoid tumors. Advances in molecular pathology have improved understanding of the underlying biology, particularly the role of WNT pathway dysregulation and beta-catenin signaling, which has led to more rational target selection and biomarker-informed approaches. As a result, drug developers are increasingly designing interventions that interrupt specific signaling cascades, and clinicians are integrating molecular profiling into diagnostic workflows to refine treatment planning.

Concurrently, the clinical paradigm has shifted toward conservative management and active surveillance for many patients, reflecting evidence that some tumors demonstrate spontaneous stabilization or slow progression. This evolution reduces unnecessary morbidity and supports the use of less invasive interventions when clinically indicated. Minimally invasive modalities, such as image-guided cryoablation, combined with precision radiotherapy techniques, have become more prominent tools for local control when intervention is required. These procedural improvements are complemented by refined systemic options: targeted therapies and repurposed kinase inhibitors are demonstrating activity with tolerability profiles that have changed risk-benefit calculations for both clinicians and patients.

Finally, the ecosystem supporting desmoid tumor research has matured through expanded patient registries, international collaborative networks, and more standardized outcome measures. These developments facilitate robust natural history studies and enable more efficient, patient-centered trial designs. Taken together, these shifts create a more predictable development pathway for innovative therapies while prioritizing functional outcomes and long-term quality of life.

Evaluation of how United States tariff changes and trade policy dynamics in 2025 can influence supply chains, clinical trial logistics, procurement strategies, and cross-border collaborations

Policy and trade dynamics play a consequential role in the availability of therapies and the functioning of global clinical development networks, and recent tariff actions in the United States for 2025 introduce a new layer of operational complexity for stakeholders engaged in desmoid tumor research and care. Tariff adjustments can affect the cost and timely importation of active pharmaceutical ingredients, medical devices, imaging equipment, and disposable supplies used in interventional procedures, thereby influencing procurement decisions at hospitals and specialty clinics. In addition, upstream supply chain perturbations can lead sponsors to reassess manufacturing footprints and contingency plans for clinical trial material distribution, particularly for multinational studies that rely on cross-border logistics.

Furthermore, tariffs can alter the economics of third-party partnerships and contract manufacturing relationships, prompting companies to evaluate reshoring, nearshoring, or diversification strategies to mitigate exposure. Changes in cross-border costs may also influence pricing discussions and reimbursement negotiations in ways that favor locally produced options or compel increased reliance on strategic stockpiles for critical inputs. For clinical operations, longer lead times for equipment and supplies may necessitate adaptive trial timelines and closer coordination with investigational sites to avoid disruptions to enrollment and patient care.

In response, organizations are increasingly incorporating trade scenario planning into risk registers and supply chain governance forums. Proactive measures include establishing multi-sourced supply chains, qualifying alternative vendors in tariff-exempt jurisdictions, and engaging early with procurement and legal teams to model potential implications. These steps help preserve continuity of care, protect trial integrity, and sustain the delivery of both established and emerging therapeutic options to patients affected by desmoid tumors.

Granular segmentation insights demonstrating how treatment modality, drug classification, tumor anatomical site, care setting, and patient age cohorts jointly shape clinical decision making and access

A nuanced segmentation perspective clarifies heterogeneity in clinical practice, access pathways, and development priorities. When analysis is organized by treatment type, stakeholders must recognize the wide therapeutic spectrum that includes anti-hormonal therapy with agents such as tamoxifen and toremifene, cytotoxic approaches including doxorubicin-based regimens, methotrexate with vinblastine, and pegylated liposomal doxorubicin, as well as nonsteroidal anti-inflammatory drugs that continue to serve a palliative role, radiation therapy for local control, surgical options for anatomically appropriate cases, and a growing class of targeted therapies aimed at molecular drivers. Each modality yields distinct efficacy and tolerability trade-offs that influence sequencing decisions.

Examining the market through the lens of drug type highlights differences between over-the-counter supportive therapies and prescription drugs that require clinician oversight and regulatory pathways. Tumor location segmentation-abdominal, extra-abdominal, and intra-abdominal-further refines clinical decision making because anatomical context dictates symptom burden, procedural feasibility, and risk tolerance for various interventions. End user segmentation underscores operational considerations, as ambulatory surgical centers, hospitals, and specialty clinics exhibit divergent infrastructure, reimbursement models, and procedural capabilities that shape where and how care is delivered.

Age group distinctions among adult, geriatric, and pediatric populations require tailored therapeutic and monitoring strategies, with particular sensitivity to long-term functional outcomes and developmental impacts in younger patients. Integrating these segmentation views enables sponsors and clinicians to prioritize evidence generation that aligns with the most critical unmet needs and to design deployment plans that reflect real-world care pathways.

Comparative regional analysis across the Americas, Europe Middle East and Africa, and Asia-Pacific that highlights access, regulatory, and infrastructure differences shaping clinical research and patient care

Regional dynamics exert a powerful influence on diagnostic practices, therapy availability, regulation, and the pace of clinical innovation. In the Americas, robust clinical research infrastructure, well-established referral networks, and an active patient advocacy community support rapid translation of promising therapies into late-stage trials, although variability in payer policies and access across subregions can affect uptake and real-world implementation. Data systems and registries in this region often facilitate longitudinal patient tracking, which enhances the quality of real-world evidence generation and post-approval monitoring efforts.

Europe, the Middle East and Africa present a heterogeneous landscape in which regulatory frameworks and reimbursement pathways vary widely. Several jurisdictions in this region emphasize health technology assessment and comparative effectiveness, prompting developers to generate evidence that demonstrates functional benefit and cost-effectiveness. In addition, centers of clinical excellence in Europe often lead collaborative trials and contribute to consensus guidance that informs international practice. Capacity constraints and differing diagnostic access in certain parts of the Middle East and Africa underline the importance of adaptable care models and targeted education programs.

The Asia-Pacific region features growing clinical research activity, increased investment in oncology infrastructure, and expanding access to innovative agents, yet it also contains substantial variability in healthcare financing and regional regulatory timelines. Strategic partnerships with regional investigators, culturally sensitive patient engagement approaches, and locally tailored evidence generation can accelerate adoption. Across all regions, cross-border collaborations and harmonized outcome measures are critical to aggregating sufficient evidence for rare conditions such as desmoid tumors, enabling regulators, payers, and clinicians to make informed decisions.

Company-level perspectives revealing partnership strategies, translational approaches, and commercialization priorities that are accelerating therapeutic options and evidence generation for desmoid tumors

The competitive and collaborative behavior of companies engaged in desmoid tumor research reveals important patterns that influence development trajectories and patient access. Innovators focusing on molecularly targeted therapies and novel mechanisms are partnering with academic centers and cooperative groups to validate biological hypotheses and accelerate proof-of-concept studies. At the same time, companies investing in reformulation, repurposing, or adaptive trial platforms are able to leverage existing safety knowledge to move more rapidly into registrational pathways when signals of efficacy emerge.

Strategic alliances between biopharma firms and specialty device manufacturers are also notable where procedural interventions such as cryoablation and image-guided therapies intersect with systemic care. Similarly, collaborations with diagnostic vendors and biomarker developers help create companion strategies that can stratify patients and optimize trial enrollment. Licensing arrangements and global partnership models remain essential for extending geographic reach, particularly when regulatory timelines differ across jurisdictions.

Commercial approaches emphasize value demonstration through functional outcomes and patient-reported metrics rather than solely tumor-centric endpoints. Companies that invest early in payer engagement and real-world evidence collection are better positioned to articulate value propositions in heterogeneous reimbursement environments. Overall, the landscape is characterized by targeted innovation, pragmatic collaboration, and increasing integration across therapeutic, diagnostic, and interventional modalities.

Actionable recommendations for industry leaders to align clinical development, supply chain resilience, reimbursement planning, and stakeholder collaboration with evolving patient needs

Industry leaders should adopt a suite of coordinated actions that translate scientific progress into sustainable clinical and commercial impact. First, development strategies must prioritize patient-centered endpoints and incorporate natural history data and registries into trial design to reduce uncertainty and enhance relevance. Adaptive trial formats and platform approaches can improve efficiency and ethical balance for a disease with variable trajectories, while biomarker-driven enrichment should be used judiciously to preserve generalizability.

Operationally, sponsors and providers should strengthen supply chain resilience by diversifying sourcing, qualifying alternate manufacturing partners, and engaging in scenario planning for trade and regulatory disruptions. Early engagement with payers and health technology assessment bodies is crucial to align evidence generation with reimbursement expectations and to shorten the time from approval to patient access. Cross-sector collaboration-linking biotech innovators, academic networks, patient groups, and specialty centers-will accelerate enrollment, standardize outcome measures, and amplify patient voice in decision making.

Finally, investment in education for clinicians, interventionalists, and multidisciplinary care teams will drive more consistent adoption of best practices, including active surveillance frameworks and minimally invasive options where appropriate. By implementing these integrated recommendations, organizations can improve patient outcomes while efficiently advancing new therapies through development and into routine care.

Transparent mixed-methods research methodology describing data sources, expert engagement, analytical frameworks, and quality controls used to generate actionable insights for stakeholders

The research underpinning this executive summary synthesizes multiple evidence streams to produce a robust, auditable set of insights. Information was compiled from peer-reviewed clinical literature, publicly available clinical trial registries, regulatory disclosures, and conference proceedings to capture both established and emerging data. In addition, qualitative inputs were obtained through structured interviews with key opinion leaders, clinical investigators, registry curators, and patient advocacy representatives to ensure that real-world perspectives augmented the scientific record.

Analytical approaches included comparative treatment pathway mapping, cross-regional policy analysis, and scenario assessment for supply chain and policy shocks. Data quality controls incorporated source triangulation, cross-validation against multiple public datasets, and iterative expert review to resolve discrepancies and contextualize findings. Where appropriate, methodological limitations are explicitly noted, including the variable maturity of evidence for newer agents and the heterogeneity inherent in observational data.

This mixed-methods approach balances rigor and pragmatism, producing insights that are actionable for clinical, commercial, and policy stakeholders while remaining transparent about evidence strength and uncertainty. The methodology supports reproducibility and allows for targeted deep dives to address specific strategic questions upon request.

Strategic conclusion synthesizing scientific progress, operational priorities, and collaborative opportunities that must align to improve outcomes for patients with desmoid tumors

The current desmoid tumor environment is defined by meaningful scientific advances, evolving clinical practice, and emergent operational challenges that together shape a complex but actionable opportunity space. Molecular discoveries and targeted therapeutic approaches are improving the probability of clinically meaningful benefit for patients, while shifts toward conservative management and function-focused endpoints underscore the importance of patient-centric development. At the same time, external pressures such as trade policy changes and supply chain variability require proactive operational strategies to preserve continuity of care and trial integrity.

Strategically, organizations that integrate rigorous evidence generation with stakeholder engagement-particularly with clinicians, payers, and patient communities-will be best positioned to translate innovation into accessible care. Collaborative trial designs, diversified supply networks, and early reimbursement dialogue are practical levers that reduce time to impact and align interventions with what patients value most. In conclusion, progress in this field is attainable through deliberate alignment of scientific rigor, operational foresight, and sustained collaboration across sectors, thereby enabling improved outcomes for individuals affected by desmoid tumors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Desmoid Tumors Market, by Treatment Type

  • 8.1. Anti-Hormonal Therapy
    • 8.1.1. Tamoxifen
    • 8.1.2. Toremifene
  • 8.2. Chemotherapy
    • 8.2.1. Doxorubicin-based regimens
    • 8.2.2. Methotrexate and Vinblastine
    • 8.2.3. Pegylated liposomal doxorubicin
  • 8.3. Cryoablation
  • 8.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 8.5. Radiation Therapy
  • 8.6. Surgery
  • 8.7. Targeted Therapy

9. Desmoid Tumors Market, by Drug Type

  • 9.1. OTC Drugs
  • 9.2. Prescription Drugs

10. Desmoid Tumors Market, by Tumor Location

  • 10.1. Abdominal
  • 10.2. Extra-Abdominal
  • 10.3. Intra-Abdominal

11. Desmoid Tumors Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Desmoid Tumors Market, by Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Desmoid Tumors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Desmoid Tumors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Desmoid Tumors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Desmoid Tumors Market

17. China Desmoid Tumors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Apotex Inc.
  • 18.6. Baxter International, Inc
  • 18.7. Bayer AG
  • 18.8. Bristol-Myers Squibb Company
  • 18.9. Cipla Limited
  • 18.10. Dr Reddys Laboratories Limited
  • 18.11. Encapsula NanoSciences LLC
  • 18.12. Fermion Oy by Orion Corporation
  • 18.13. Hetero Healthcare Limited.
  • 18.14. Immunome, Inc.
  • 18.15. Intelicure Lifesciences
  • 18.16. Iterion Therapeutics
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Mayne Pharma Group Limited
  • 18.19. Medichem, S.A.
  • 18.20. Natco Pharma Limited
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. SpringWorks Therapeutics, Inc.
  • 18.24. Sun Pharmaceutical Industries Limited
  • 18.25. Synthon International Holding B.V.
  • 18.26. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DESMOID TUMORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DESMOID TUMORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DESMOID TUMORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DESMOID TUMORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY TAMOXIFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY TAMOXIFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY TAMOXIFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY TOREMIFENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY TOREMIFENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DESMOID TUMORS MARKET SIZE, BY TOREMIFENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DESMOID TUMORS MARKET SIZE, BY DOXORUBICIN-BASED REGIMENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DESMOID TUMORS MARKET SIZE, BY DOXORUBICIN-BASED REGIMENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DESMOID TUMORS MARKET SIZE, BY DOXORUBICIN-BASED REGIMENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DESMOID TUMORS MARKET SIZE, BY METHOTREXATE AND VINBLASTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DESMOID TUMORS MARKET SIZE, BY METHOTREXATE AND VINBLASTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DESMOID TUMORS MARKET SIZE, BY METHOTREXATE AND VINBLASTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEGYLATED LIPOSOMAL DOXORUBICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEGYLATED LIPOSOMAL DOXORUBICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEGYLATED LIPOSOMAL DOXORUBICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DESMOID TUMORS MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DESMOID TUMORS MARKET SIZE, BY CRYOABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DESMOID TUMORS MARKET SIZE, BY CRYOABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DESMOID TUMORS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DESMOID TUMORS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DESMOID TUMORS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DESMOID TUMORS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DESMOID TUMORS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DESMOID TUMORS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DESMOID TUMORS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DESMOID TUMORS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DESMOID TUMORS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DESMOID TUMORS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DESMOID TUMORS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DESMOID TUMORS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DESMOID TUMORS MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DESMOID TUMORS MARKET SIZE, BY OTC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DESMOID TUMORS MARKET SIZE, BY OTC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DESMOID TUMORS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DESMOID TUMORS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DESMOID TUMORS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DESMOID TUMORS MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DESMOID TUMORS MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DESMOID TUMORS MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DESMOID TUMORS MARKET SIZE, BY EXTRA-ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DESMOID TUMORS MARKET SIZE, BY EXTRA-ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DESMOID TUMORS MARKET SIZE, BY EXTRA-ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DESMOID TUMORS MARKET SIZE, BY INTRA-ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DESMOID TUMORS MARKET SIZE, BY INTRA-ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DESMOID TUMORS MARKET SIZE, BY INTRA-ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DESMOID TUMORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DESMOID TUMORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DESMOID TUMORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DESMOID TUMORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DESMOID TUMORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DESMOID TUMORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DESMOID TUMORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DESMOID TUMORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DESMOID TUMORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DESMOID TUMORS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DESMOID TUMORS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DESMOID TUMORS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DESMOID TUMORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DESMOID TUMORS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DESMOID TUMORS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS DESMOID TUMORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DESMOID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GCC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. G7 DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. NATO DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 190. NATO DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. NATO DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES DESMOID TUMORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA DESMOID TUMORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)